Author: admin

  • How Climate Change Is Threatening Summer Tours and Festivals

    How Climate Change Is Threatening Summer Tours and Festivals

    In late July, Willie Nelson was onstage during his set on the Outlaw Music Festival tour in Raleigh, North Carolina, when tour manager John Selman noticed an abrupt shift in the weather. During his 20-plus years working with Nelson, Selman has dealt with the elements, but nothing like what he was seeing suddenly descend upon them. “This one was too big and too strong and there was heavy lightning,” Selman says. “It wasn’t good.” Waiting until Nelson had finished a song, Selman whisked him and his band offstage and into a bus — just as intense rain and lightning erupted all around them. “Afterwards, Willie thanked me,” Selman says. “He said, ‘Good call.’”

    As Rolling Stone has reported, the impact of climate change on festivals and outdoor live music has been building over time. In the last few years, Beyoncé, Pink, and Noah Kahan, among others, have had concerts canceled or delayed by extreme lightning, rain, or wildfire smoke. The summer 2025 concert season wasn’t necessarily worse than other recent years, but more ferocious and erratic weather patterns continued to wreak havoc on the live music world.

    During their summer tour, folk-rock band the Head and the Heart had to endure two extreme-weather situations. A show in Nashville was shut down due to approaching lightning, and another, an outdoor gig in Asbury Park, New Jersey, was canceled when the state issued a state of emergency over extreme storms. “It’s definitely been an anomaly for us,” says drummer Tyler Williams. “I don’t think we’ve ever canceled a show due to weather, and we’ve been touring heavily for 15 years. We’ve experienced a few humid, extreme summers, but this felt different.”

    Not surprisingly given the season, festivals were especially slammed on weather-related fronts. Most conspicuously, this year’s Bonnaroo Music & Arts Festival was canceled after its first day due to what organizers called “significant and steady precipitation.” Bonnaroo organizers declined comment to Rolling Stone for this story, but Tim “Tuba” Smith of C3 Presents, which produces the festival, told The Tennessean this week, “The weather has been consistently worse than what the forecasts were. Safety is always the first concern here. It takes a lot to get 30,000 cars out of the property, and so we made that difficult decision … we did the best that we could.”

    Bonnaroo 2025 was canceled after just one day due to extreme weather.

    Douglas Mason/WireImage

    Beyond the Raleigh show in July, this year’s Outlaw Music Festival faced other challenges. Co-headliner Bob Dylan’s set at the Gorge in Washington state had to end prematurely due to inordinately heavy winds. A show in Ridgedale, Missouri, was canceled roughly halfway through, thanks to another weather-pattern change. “It got extremely hot, the humidity was thick, and all of a sudden it got really cold and windy,” says Selman. “When that all collided, it caused chaos. We had a tent onstage to cover the gear, and it flew off like a parachute. We had to make that decision [to cancel] in 10 minutes.” Nelson’s famed guitar, Trigger, was on his bus and unharmed, but other gear and equipment were so soaked or damaged that the next stop on the tour, in Oklahoma, had to be nixed as well.

    In Los Angeles, the annual Outloud festival, held in tandem with Pride Month in early June, was faced with inordinately high temperatures for that time of year. “In the two weeks leading up to the show, it looked like it was going to be hotter than usual,” Outloud founder Jeff Consoletti says. “We were seeing temperatures we hadn’t seen in L.A., in the high 80s.” After meeting with city officials, the festival added more water stations and shaded areas. Even then, adds Consoletti, “We didn’t see any life-threatening situations, but we saw an increase in the number of attendees who were dehydrated and had mild heat stroke.”

    Inclement weather has long been the bane of festivals and outdoor tours, and differentiating between climate change and a stretch of bad storms can be tricky. But those in the live music world still feel the change is noticeable. “Extreme heat is the problem now,” says Stephen Parker of the National Independent Venue Association (NIVA). “We need to make sure venues have more cooling stations and in-and-out privileges for festivalgoers who can escape the heat in their car or in neighboring businesses. It’s a constant consideration now.”

    An increase in lightning is also in the air. In July, a severe lightning storm headed toward the Great South Bay Music Festival on Long Island kept at least 1,500 customers away during its reggae night, featuring Stephen and Damian Marley. The storm wound up changing course, but according to founder Jim Faith, who has faced flooding at his festival in the past, “Anyone thinking of coming or on their way was changing their mind and not coming. The rain is bad enough. That’s what we used to worry about. But more lightning is the new thing. That’s a different animal.”

    Other artists have cited similar factors in their decision-making this year. Steve Miller canceled his band’s summer shows thanks to what he called “the combination of extreme heat, unpredictable flooding, tornadoes, hurricanes and massive forest fires” that “makes these risks for you our audience, the band and the crew unacceptable.”  

    Speculation was rampant that supposedly low ticket sales were another reason for the nixed tour. Miller declined to comment, but in a social media post, Miller’s bassist, Kenny Lee Lewis, rebutted those rumors, doubling down on the weather explanation: “You didn’t see Steve Miller hanging over a railing after our first outdoor stadium show opening in the sun for Journey and Def Leopard in Atlanta trying to fend off heat exhaustion. … Next couple outdoor shows the crew had to arrange the stage air coolers with flexible ducts on him as he also wore frozen gel packs on his neck and shoulders. He looked like the Michelin Man! And he still almost passed out.” (A source in the concert business supports Miller’s claim about climate change.)

    Echoing Miller’s methods of lowering onstage temperatures, Nelson, since 2021, has been carting around a portable air-conditioning unit (dubbed “Chilly Nelson” by his crew) to blow cool air onto the stage. The Head and the Heart’s touring gear includes a cold-plunge tub for the band to cool off backstage. “We use it just to feel better after shows,” Williams says. “But it’s become more of a necessity.”

    Weather concerns have been building in the live music business for years. These concertgoers tried to stay dry at a 2024 Black Eyed Peas show in Pennsylvania.

    Lisa Lake/Getty Images

    As Guster has learned, the newly unpredictable climate can also impact musicians’ wallets. According to singer-guitarist Adam Gardner, insurance for events has gone up so much, thanks to the new risk factor of climate change, that bands like his are literally paying the price. “House expenses have gone up because the insurance went up, and they’re passing some of that along to the artists,” says Gardner, who also runs Reverb, a nonprofit aiming to create a “sustainable music industry.” “All of a sudden, our potential net income is thousands of dollars less, because of the risk of putting on a show outside.”

    Trending Stories

    How climate change will impact festivals and outdoor tours remains as unpredictable as some of the storms that suddenly descend upon them. Some foresee indie festivals not surviving at all or, in the future, moving from summer to fall, or switching to inside venues. “Moving indoors into pre-existing infrastructures is probably the biggest change we’re seeing in festivals,” says NIVA’s Parker. “It not only cuts down on the risk of extreme weather, but you don’t have to set up a stage. That’s a more realistic logistical future for festivals, and it also minimizes the impact of climate change.”

    Consoletti feels it would be “a bummer” to move his Outloud gathering into an indoor structure: “There’s something really special about people gathering and enjoying an artistic moment outdoors.” But as the live music business is learning, nothing is off the table anymore. “I think of us as an outdoor band,” says the Head and the Heart’s Williams. “Our music goes well with nature. Playing those sheds and storied amphitheaters is really fun. A lot of our fans don’t like to go to arenas, so we may have to train our fans to go there. People like to be outside.”

    Continue Reading

  • Why Man Utd are determined to sign Carlos Baleba as Red Devils draw up plans for big-money transfer in 2026

    Why Man Utd are determined to sign Carlos Baleba as Red Devils draw up plans for big-money transfer in 2026

    • Man Utd still keen on Baleba
    • Red Devils missed out in summer
    • Brighton thought to want £115m

    Follow GOAL on WhatsApp! 🟢📱

    Continue Reading

  • Iraq’s premier says he hopes producers will reconsider oil export quota – Markets

    Iraq’s premier says he hopes producers will reconsider oil export quota – Markets

    BAGHDAD: Iraq hopes fellow producers will reconsider its oil export quota to better reflect its production capacity, Prime Minister Mohammed Shia al-Sudani said on Saturday, a day ahead of an OPEC+ meeting in a rare public comment by a senior Iraqi official.

    Iraq, the group’s largest overproducer, is under pressure from the Organization of the Petroleum Exporting Countries to cut output to compensate for having produced more than its agreed volume.

    It is among countries that submitted plans in April to make further oil output cuts to compensate for pumping above agreed quotas.

    Iraq’s oil exports averaged 3.38 million barrels per day in August, according to the oil ministry. September average oil exports are expected to be between 3.4 million bpd and 3.45 million, the chief of the state oil company SOMO said on Saturday.

    OPEC counts oil flows from Kurdistan as part of Iraq’s quota.

    Sudani previously appealed publicly for a review of Iraq’s production quota in late 2022.

    OPEC+, which includes OPEC members plus Russia and other allies, has reversed its strategy of output cuts from April and has already raised quotas by some 2.5 million barrels per day, about 2.4% of world demand.

    Oil heads for weekly loss as higher supply expected

    The move is intended to boost market share and follows pressure from U.S. President Donald Trump to lower oil prices.

    Eight countries from OPEC+ are set to meet online on Sunday to consider a further output hike.

    Another output boost would mean OPEC+, which pumps about half of the world’s oil, would be starting to unwind a second layer of cuts of about 1.65 million barrels per day, or 1.6% of world demand, more than a year ahead of schedule.

    Responding to a question about Sunday’s meeting, Iraq’s OPEC representative Ali Nazar said attention was focused on balancing the market, whether through increases, maintaining current production, or cuts.

    Separately, Sudani also said there would be arrangements to facilitate the entry of major oil companies to Iraq.

    In the past two years, Iraq has signed agreements with oil majors that had previously retreated from the country, including Chevron, France’s TotalEnergies and UK oil major BP.

    Continue Reading

  • New medication lowered hard-to-control high blood pressure in people with chronic kidney disease

    New medication lowered hard-to-control high blood pressure in people with chronic kidney disease

    Research Highlights:

    • Results from the FigHTN Phase 2 clinical trial showed baxdrostat, a new medication that inhibits the production of the hormone aldosterone, lowered systolic blood pressure by about 5% when added to the existing medications taken by people with chronic kidney disease and who also have uncontrolled high blood pressure.
    • The analysis also found that baxdrostat lowered the loss of albumin in the urine, which is a marker of kidney and cardiovascular risk, by 55% compared to placebo, suggesting that this medication may help delay the progression of kidney disease .
    • These findings suggest the potential for baxdrostat to improve longer-term health outcomes like kidney and cardiovascular conditions and reduce the need for higher-cost care for people with uncontrolled high blood pressure and chronic kidney disease.
    • Note: The study featured in this news release is a research abstract. Abstracts presented at the American Heart Associations scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

    Embargoed until 9:45 a.m. ET/8:45 a.m. CT, Saturday, Sept. 6, 2025

    BALTIMORE, Sept. 6, 2025 — Adding the novel medication baxdrostat to standard care may help manage high blood pressure and delay the progression of kidney disease in people with chronic kidney disease and uncontrolled high blood pressure , according to preliminary research presented at the American Heart Association’s Hypertension Scientific Sessions 2025. The meeting is in Baltimore, September 4-7, 2025, and is the premier scientific exchange focused on recent advances in basic and clinical research on high blood pressure and its relationship to cardiac and kidney disease, stroke, obesity and genetics. This study is simultaneously published today in the Journal of the American Society of Nephrology.

    Chronic kidney disease and high blood pressure are closely linked and, when not managed appropriately, can lead to serious outcomes such as heart attack, stroke, heart failure and progression to kidney failure. Aldosterone, a hormone produced by the adrenal glands, can play a role in both high blood pressure and chronic kidney disease. Aldosterone causes sodium to be retained, which increases water retention and blood pressure. Over time, an excess of the hormone can lead to stiffening and thickening of blood vessels, which can contribute to heart damage and cause scarring in the kidneys, thereby playing a role in both high blood pressure and chronic kidney disease.

    “These findings are encouraging for people living with chronic kidney disease and high blood pressure, two conditions that often go hand-in-hand and create a dangerous cycle,” said lead study author Jamie P. Dwyer, M.D., a professor of medicine in the division of nephrology and hypertension at University of Utah Health in Salt Lake City. “High blood pressure can worsen kidney function and declining kidney function can further elevate blood pressure, and these outcomes can be life-altering for patients.”

    The study was designed to find whether adding baxdrostat to standard care is safe and could help lower blood pressure in people who have both chronic kidney disease (serious enough that they are likely to develop kidney failure or require a transplant during their lifetime ) and uncontrolled high blood pressure. Their blood pressure has remained high despite already taking either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), two medications that work on a group of hormones that act together to regulate blood pressure.

    At the beginning of the study, participants had an average systolic (top number) blood pressure of 151 mm Hg despite treatment and evidence of kidney disease on laboratory testing. When the protein albumin was measured in the urine, the average level for participants was 714 mg/gm of creatinine; levels of 30 or higher may be a sign of chronic kidney disease. When a blood sample was used to measure the estimated glomerular filtration rate (eGFR, a key indicator of kidney function), the average level was 44mL/min/1.73. Levels that are persistently less than 60 suggest chronic kidney disease.

    Of 195 initial study participants, 192 were randomized to begin treatment with low-dose (0.5 mg-1 mg) or high-dose baxdrostat (2 mg-4 mg) or a placebo in addition to standard care. Three people finished the study early due to adverse events, their own decision to leave the study or for other reasons.

    After 26 weeks:

    • The average systolic blood pressure had fallen 8.1 mm Hg more in participants receiving either dose of baxdrostat than in those receiving the placebo, a reduction of about 5%.
    • High potassium levels in the blood, a known side effect of medications that block the renin-angiotensin-aldosterone system, occurred in 41% of participants on baxdrostat and 5% of those on placebo. Most cases were mild to moderate.
    • There were no deaths or unanticipated adverse events during the trial, however, 9% of participants taking baxdrostat and 3% of those in the placebo group experienced a serious adverse event.

     In an exploratory analysis, the researchers looked at the amount of albumin lost in the urine, a type of protein that when found in the urine in high amounts is a predictor of cardiovascular and kidney disease. They found the urine albumin level was 55% lower in those taking baxdrostat than in those taking a placebo, comparable to the reduction seen with medications that delay the progression of kidney disease.

    “The reduction in urine albumin gives us hope that baxdrostat may also help delay kidney damage. This potential is now being tested in two large Phase 3 trials to determine if baxdrostat delays the progression of kidney disease,” said Dwyer.

    “These new findings are reassuring that this new class of antihypertensive medications are likely to have both kidney- and cardio-protective benefits and to be safe and effective for broad patient populations,” said Jordana B. Cohen, M.D., M.S.C.E., immediate past chair of the American Heart Association’s Hypertension and Kidney Cardiovascular Science Committee. “Patients with chronic kidney disease were historically often excluded from drug studies. It is particularly reassuring to know that patients with chronic kidney disease, who have very high rates of hypertension and elevated renin-angiotensin aldosterone activity, were represented in their own study, tolerated the medication well, and had both blood pressure and albuminuric benefits. This medication class could be a game changer in the management of hypertension in this patient group.” Cohen, who was not involved in this study, is deputy director and associate professor of medicine and epidemiology in the Perelman School of Medicine at the University of Pennsylvania.

     Study details, background and design:   

    • The study included 195 people with an average age of 66 years. Of the participants, 32% were women, 40% were non-Hispanic white and 80% had Type 2 diabetes. The study was conducted at 71 sites in the United States. Three participants were not randomized or included in the final analysis.
    • All participants had uncontrolled high blood pressure (systolic blood pressure of 140 mm Hg or higher, or 130 mm Hg or higher for people with Type 2 diabetes ) despite taking the maximum tolerated dose of either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker among their medications, with average systolic blood pressure of 151.2 mm Hg at the start of the study.
    • All participants also had chronic kidney disease but were not in kidney failure (eGFR of 25-75 mL/min/1.73, average eGFR of 44 mL/min/1.73 at the start of the study; and urine albumin-creatinine ratio of 100 mg/g or higher, average of 713.8 at the start of the study ).    
    • The 192 participants were randomized to one of the three treatment groups: low-dose baxdrostat (0.5 mg/day, increasing to 1 mg/day after two weeks); high-dose baxdrostat (2 mg/day, increasing to 4 mg/day after two weeks); or a placebo.
    •  After 26 weeks, blood pressure and kidney function tests were repeated, and the primary analysis compared changes in systolic blood pressure among the three groups. Adverse events were also reported for each of the three treatment groups.
    • Baxdrostat is in a class of medications that inhibit the production of aldosterone and are being tested for their ability to treat conditions such as high blood pressure, chronic kidney disease and heart failure. Baxdrostat is not approved for any use by the U.S. Food and Drug Administration.

    Note: Oral presentation #061 is at 9:45 a.m. ET, Saturday, Sept. 6, 2025.

    Co-authors and their disclosures and funding sources are listed in the abstract. The study was funded by AstraZeneca, developer of baxdrostat..

    Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal. 

    The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.

    Additional Resources:

    ###

    The American Heart Association’s Hypertension Scientific Sessions 2025 is a premier scientific conference dedicated to recent advancements in both basic and clinical research related to high blood pressure and its connections to cardiac and kidney diseases, stroke, obesity and genetics. The primary aim of the meeting is to bring together interdisciplinary researchers from around the globe and facilitate engagement with leading experts in the field of hypertension. Attendees will have the opportunity to discover the latest research findings and build lasting relationships with researchers and clinicians across various disciplines and career stages. Follow the conference on X using the hashtag #Hypertension25.

    About the American Heart Association

    The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.

    For Media Inquiries and AHA Expert Perspective:

    AHA Communications & Media Relations in Dallas: 214-706-1173; ahacommunications@heart.org

    Michelle Kirkwood: Michelle.Kirkwood@heart.org

    For Public Inquiries: 1-800-AHA-USA1 (242-8721)

    heart.org and stroke.org

    Continue Reading

  • England: Elliot Anderson set to make international debut

    England: Elliot Anderson set to make international debut

    Nottingham Forest midfielder Elliot Anderson is set to make his England debut against Andorra.

    Anderson, given his first call-up by head coach Thomas Tuchel at the end of last month, gets the nod in the 2026 World Cup qualifier at Villa Park later on Saturday (17:00 BST).

    He will partner Arsenal duo Declan Rice and Eberechi Eze in midfield.

    Dan Burn is set to play next to Marc Guehi at centre-back, with Reece James and Myles Lewis-Skelly at full-back.

    Harry Kane will captain the side as central striker, with Marcus Rashford and Noni Madueke playing out wide.

    Jordan Pickford will start in goal.

    Continue Reading

  • TIFF 2025: Aaron Taylor-Johnson, Theo James lead heist thriller 'Fuze' – Reuters

    1. TIFF 2025: Aaron Taylor-Johnson, Theo James lead heist thriller ‘Fuze’  Reuters
    2. Theo James, Aaron Taylor-Johnson Ignite Heist Thriller ‘Fuze’  Variety
    3. ‘Fuze’ Review: David Mackenzie’s London-Set Thriller Opens With A Bang And Doesn’t Let Up – Toronto Film Festival  Deadline
    4. ‘Fuze’ First Look: Aaron Taylor-Johnson and Theo James Lead a ‘Hard-Boiled’ Bomb Thriller (Exclusive)  People.com
    5. ‘Fuze’ Review: David Mackenzie’s Literal Ticking Time Bomb Thriller Isn’t Sure What to Do After Detonating  IndieWire

    Continue Reading

  • US extends humanitarian assistance to flood-hit Pakistan – RADIO PAKISTAN

    1. US extends humanitarian assistance to flood-hit Pakistan  RADIO PAKISTAN
    2. US sends humanitarian relief to Pakistan’s flood-hit areas  The Express Tribune
    3. Aid flows as country reels from floods  Dawn
    4. World News in Brief: Pakistan floods, countries lag on climate reporting, concern over attack on peacekeepers in south Lebanon, cuts hit human rights investigations  UN News
    5. Several US military aircraft land at Pakistan’s Nur Khan base, destroyed by India during Operation Sindoor; r  India.Com

    Continue Reading

  • NASA study reveals space travel accelerates aging

    NASA study reveals space travel accelerates aging



    NASA study reveals space travel accelerates aging

    A National Aeronautics and Space Administration (NASA) study found that space travel damaged blood cells, causing them to age faster. 

    This could pose a significant problem for astronauts on long space missions.

    According to the study author, Dr. Catriona Jamieson, director of the Sanford Stem Cell Institute at the University of California, San Diego, “Space is the ultimate stress test for the human body.”

    Researchers used AI-powered imaging tools to monitor changes in human cells sent to the ISS on four SpaceX missions. Scientists sent human cells to space and used AI tools to track how they changed.

    The study found that when cells that produce blood and support the immune system were exposed to space for 30-45 days, they began to deteriorate.

    They lost their ability to produce healthy new cells and exhibited signs of damage, including DNA harm and shorter telomeres.

    The study author, Jamieson, stated that these findings are crucial because space stressors, such as radiation and microgravity can accelerate cellular ageing. However, some damaged cells showed signs of recovery when returned to a healthy environment on Earth. The findings were published in the Journal Cell Stem Cell.

    The researchers now plan to study astronauts’ molecular changes during space missions to develop medical or genetic countermeasures that protect human health.

    This could lead to new strategies for mitigating the adverse effects of space travel.

    Continue Reading

  • Modi reaffirms ‘very positive’ US ties after Trump downplays rift – Samaa TV

    1. Modi reaffirms ‘very positive’ US ties after Trump downplays rift  Samaa TV
    2. Indian PM Modi says ties with US still ‘very positive’  Dawn
    3. Trump says India and Russia appear ‘lost’ to ‘deepest, darkest China’  Reuters
    4. US-India Relations Strained by Shifting Alliances and Economic Pressures  Global Trade Magazine
    5. “Trump realised he was wrong about India…”: Ex-diplomat Fabian on US President’s softened tone  ANI News

    Continue Reading

  • US offers tariff exemptions to trade partners on selected goods

    US offers tariff exemptions to trade partners on selected goods



    US President Donald Trump speaks with the media in the Oval Office, at the White House in Washington, DC, US, September 5, 2025. — Reuters 

    US President Donald Trump has signed an executive order allowing tariff exemptions, starting Monday, for trade partners that secure deals covering metals, chemicals and pharmaceutical compounds.

    Trump has spent his first seven months in office building up massive tariff increases to reorder the global trading system, cut US trade deficits and extract concessions from trading partner countries in negotiations.

    His latest order identifies more than 45 categories for zero import tariffs from “aligned partners” who clinch framework pacts to cut Trump’s “reciprocal” tariffs and duties imposed under the Section 232 national security statute.

    Friday’s order brings US tariffs in line with its commitments in existing framework deals, including those with allies such as Japan and the European Union.

    The exemptions for countries with US trade deals are set to begin at 12:01am EDT/0401 GMT on Monday, it said.

    In the order, Trump says his willingness to reduce tariffs depends on the “scope and economic value of a trading partner’s commitments to the United States in its agreement on reciprocal trade” and US national interests.

    The cuts cover items that “cannot be grown, mined, or naturally produced in the United States” or produced in sufficient volume to meet domestic demand.

    A White House official said it also creates new carveouts for some agricultural products, aircraft and parts, and non-patented articles for use in pharmaceuticals.

    In situations where a country has struck a “reciprocal” trade deal with the United States, this will allow the US Trade Representative, the Commerce Department and customs to waive tariffs on covered imports without a new executive order from Trump, the official said.

    The zero-tariff items identified in the order include graphite and various forms of nickel, a key ingredient in stainless steel manufacturing and electric vehicle batteries.

    Also covered are compounds used in generic pharmaceuticals, including the anesthetic lidocaine and reagents used in medical diagnostic tests.

    The order encompasses various types of gold imports, from powders and leaf to bullion, a key import from Switzerland, which is struggling with US tariffs of 39% as it has not yet reached a trade deal.

    The order also permits tariffs to be scrapped on natural graphite, neodymium magnets, light-emitting diodes (LEDs) and eliminates previous tariff exemptions on certain plastics and polysilicon, a key component of solar panels.

    Continue Reading